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Abstract
Background: Measurement of late-night salivary cor-
tisol concentrations is increasingly used as a screen-
ing test in suspected Cushing’s syndrome. Cortisol
concentrations are typically extremely low in late-
night samples and discordant assay-specific reference
ranges have been reported. Therefore, the aim of our
study was to assess the analytical performance of the
first automated cortisol immunoassay specified for
salivary measurements and to establish late-night
sampling reference-range data for this test.
Methods: Salivary cortisol was measured using the
Roche Cobas Cortisol assay (Roche Diagnostics). Five
salivary pools in different concentration ranges were
used to assess the inter-assay imprecision of this test
in a two-centre evaluation protocol including two re-
agent lots. Linearity was tested by serial dilution. Sal-
ivary samples were obtained at 23:00 h from 100
apparently healthy volunteers using a commercially
available salivary sampling device (Salivette, Sar-
stedt). A subset of 20 samples was used for method
comparison with isotope dilution liquid chromatog-
raphy-tandem mass spectrometry.
Results: Inter-assay coefficients of variation (ns20)
between 11.6% and 40.4% were found for mean cor-
tisol concentrations between 12.9 and 2.6 nmol/L,
with an estimated functional sensitivity of approxi-
mately 5.0 nmol/L. The test also gave linear results in
the lowest concentration range between 1.0 and
8.3 nmol/L. Mean late-night salivary cortisol of
5.0 nmol/L was found for healthy individuals; the
absolute range was 1.4–16.7 nmol/L, and the 95th per-
centile was 8.9 nmol/L. Substantially lower concentra-
tions were found with isotope dilution LC-MS/MS
compared to immunoassay results (mean concentra-
tions 1.8 and 4.4 nmol/L, respectively).
Conclusions: The automated assay investigated was
found to offer acceptable analytical performance in
the very low concentration range required for late-
night salivary cortisol, despite a very short turn-
around time. Using this assay, late-night salivary
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cortisol concentrations below 8.9 nmol/L are typically
found in healthy volunteers.
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Introduction
Early signs of Cushing’s syndrome are unspecific and
may include weight gain, plethora, hypertension, glu-
cose intolerance, depression, and irregularities of the
menstrual cycle. Very similar presentations are com-
mon in insulin resistance syndrome and in polycystic
ovary syndrome. It is not uncommon that Cushing’s
syndrome is diagnosed only in advanced disease
states several years after the onset of symptoms, and
so the disease is typically associated with substantial
morbidity and mortality (1, 2). Mild forms of
Cushing’s syndrome, however, probably often remain
undiagnosed in obese diabetic patients (3, 4). There-
fore, reliable and convenient screening tests for
Cushing’s disease are of particular clinical impor-
tance. Standard laboratory investigations performed
to rule out Cushing’s syndrome include the dexame-
thasone suppression test, quantification of 24-h free
urinary cortisol, and determination of midnight serum
cortisol concentrations. Meanwhile, growing evidence
suggests measurement of midnight or late-night sal-
ivary cortisol as a useful and convenient non-invasive
method to be applied in the screening for Cushing’s
disease (5–7). In investigations carried out so far,
laborious and typically radioactivity-based manual
tests for salivary cortisol determination have been
used (8–14). To date, only one automated cortisol
immunoassay has specified saliva as a suitable sam-
ple material (Roche Cobas Cortisol) (15, 16). However,
conclusive reference ranges have not been reported
for this assay so far, and data published on the ana-
lytical performance of this test are limited. We there-
fore decided to validate this assay with a particular
focus on reproducibility and agreement with an iso-
tope dilution mass spectrometric method and to




The Roche Cobas Cortisol assay was used on an Elecsys
2010 immunoanalyser system (Roche Diagnostics, Mann-
heim, Germany). This is a competitive electrochemilumines-
cence immunoassay (ECLIA) using polyclonal sheep anti-
cortisol antibodies. A 20-mL sample is incubated with a cor-
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Table 1 Investigation of dilution linearity with saliva as the
sample material for the Roche Cobas cortisol assay.
Observed Expected





Conversion of units for cortisol: wnmol/Lx=0.0362™wmg/dLx;
wmg/dLx=27.6™wnmol/Lx.
tisol-specific biotinylated antibody and a Tris(2,29-bipyridyl)
ruthenium(III)-labelled cortisol derivative. Subsequently,
streptavidin-coated paramagnetic microparticles are added.
Biotinylated antibodies bind to streptavidin on the micropar-
ticles. This complex is magnetically captured onto the sur-
face of an electrode in the measurement cell. Application of
a voltage to the electrode induces chemiluminescence of the
ruthenium complex; the light signal is quantified by a pho-
tomultiplier. The total analysis time is 18 min. The lower limit
of quantitation of the method is 0.5 nmol/L.
Sample collection
For collection of saliva, a commercially available sampling
device was used (Salivette, Sarstedt, Nu¨mbrecht, Germa-
ny). The system contains a polyester swab that is chewed by
the patient for approximately 1 min. Patients are instructed
not to eat or drink for 1 h prior to sampling. The swab is then
introduced into the system and capped. After centrifugation
of the cartridge for 10 min, typically 500 mL of saliva is
obtained in the lower portion of the sampling system. The
system does not contain any preservative.
To prove that the sampling swab itself was free from com-
pounds interacting with the immunometric cortisol deter-
mination, a swab was eluted with 500 mL of system diluent
(Elecsys Diluent Universal, Roche) and the eluate was ana-
lysed using the Cobas Cortisol test. A concentration below
the lower limit of detection was reported by the analytical
system.
Assay validation
To assess the linearity of the method, saliva was sampled
from a healthy volunteer at 08:00 h. This sample material
was serially diluted 1:1 with the sample diluent of the cortisol
assay (Elecsys Diluent Universal) in three steps. Cortisol was
measured in duplicate in these four samples to compare the
measured and expected results.
To investigate the imprecision of the method, saliva pools
were prepared from specimens sampled from a healthy vol-
unteer at different times. The pools were divided into ali-
quots and stored at y208C until analysis. The imprecision
study was performed in two centres for five saliva pools.
Analysis was thus performed in ten independent series at
the University of Munich (centre 1), and at the University of
Halle (centre 2). In the two centres, different reagent lots
were used. In both centres the analyser systems were in rou-
tine use for a variety of analytes during the investigation
period. Calibration and all maintenance procedures were
performed as recommended by the manufacturer (re-calibra-
tion after 28 days). Quality control was performed according
to the guidelines of the German Medical Association for
quality assurance in medical laboratories using commercial
quality control materials (Biorad Lyphocheck Immunoassay
Controls, Biorad, Hercules, CA, USA; cortisol target concen-
trations 63.5 and 830 nmol/L).
Reference range investigation
Saliva samples were obtained from 100 apparently healthy
volunteers who gave informed consent to participation in
this investigation. Only individuals without relevant acute or
chronic health complaints were included. This was docu-
mented by the participants in a health questionnaire. Body
weight and height were assessed, as was the use of drugs.
Women taking hormonal contraceptive drugs were not
excluded. The participants were instructed to take the sam-
ples at 23:00 h. The samples were frozen within 12 h after
sampling and stored at y208C until analysis. Measurements
were performed in two analytical series in the Institute of
Clinical Chemistry of the University of Munich.
Method comparison
A total of 20 saliva samples were used for a method com-
parison study between the Cobas Cortisol assay and an iso-
tope dilution liquid chromatography-tandem mass
spectrometry (ID-LC-MS/MS) method (eight pooled samples,
and 12 randomly selected samples from the reference range
investigation). In the ID-LC-MS/MS method, tri-deuterated
cortisol was used as the internal standard. After addition of
the internal standard solution (50 mL, concentration
5.520 nmol/L) to 500-mL samples and equilibration for
10 min, solvent extraction with dichloromethane was per-
formed for 20 min on a horizontal shaker. The organic phase
was dried under a stream of nitrogen. The extract was taken
up in 100 mL of methanol/water (80:20 v/v). HPLC separation
was performed on a 120=4 mm C18 column using a gradi-
ent programme. The injection volume was 50 mL. For detec-
tion, a Waters Micromass Quattro Ultima Pt MS/MS system
was used in positive electrospray ionisation mode. For cor-
tisol the mass transition 363™121 was recorded, and for tri-
deuterated cortisol used as the internal standard, the mass
transition 366™121 was monitored. The retention time for
cortisol and the deuterated internal standard was 7.2 min,
and the total run time was 15 min.
The study protocol was approved by the institutional
Review Board.
Results
The cortisol assay was linear between 1.0 and
8.3 nmol/L (Table 1).
The results for the two-centre imprecision study
including five saliva pools analysed in a total of 20
series using different reagent lots are given in Table
2 and Figure 1.
Of the 100 healthy volunteers included in the refer-
ence range investigation, 47 were female and 53 were
male. The mean age was 38 years (range 14–59 years)
and the mean body mass index was 25.7 kg/m2 (medi-
an 24.9, range 18.8–38.6 kg/m2). Fourteen participants
took hormonal contraceptive drugs.
The mean cortisol concentration found in the sam-
ples taken at 23:00 h was 5.0 nmol/L (SD 2.4, median
4.7 nmol/L). The absolute range was 1.4–16.7 nmol/L
and the interquartile range was 3.2–6.2 nmol/L. The
95th percentile was 8.9 nmol/L. The distribution of the
concentrations found is shown in Figure 2.
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Table 2 Results of the two-centre imprecision study of the Roche Cobas Cortisol assay with saliva as the sample material.
Pool A Pool B Pool C Pool D Pool E
Pooled data Mean, nmol/L 12.9 11.2 6.3 3.2 2.6
CV, % 11.6 11.9 16.4 27.1 40.4bca
Centre 1 Mean, nmol/L 14.0 12.1 7.0 3.7 3.2
CV, % 6.3 9.7 12.8 22.1 34.3
Centre 2 Mean, nmol/L 11.4 10.2 5.5 2.6 1.9
CV, % 5.9 5.1 5.2 16.3 8.1
Conversion of units for cortisol: wnmol/Lx=0.0362™wmg/dLx; wmg/dLx=27.6™wnmol/Lx.
Figure 1 Precision profile of the Cobas Cortisol assay
derived from data for the two-centre precision study.
Figure 2 Distribution of 23:00-h salivary cortisol concentrations found in 100 apparently healthy adults using the Roche Cobas
Cortisol assay.
Mean late-night salivary cortisol was 5.0 nmol/L in
individuals with a body mass index below 30 kg/m2,
and 5.1 nmol/L in individuals with a body mass index
above 30 kg/m2 (ns17); this difference was not sig-
nificant (Wicoxon test). Concentrations found in wom-
en and men did not differ significantly. There was no
significant difference in salivary cortisol concentra-
tions for women taking hormonal contraceptive drugs
compared to individuals not taking such drugs.
For the 20 saliva samples included for method com-
parison, substantially lower concentrations were
found by ID-LC-MS/MS compared to the Cobas immu-
noassay (mean cortisol: immunoassay, 4.4 nmol/L; ID-
LC-MS/MS 1.8 nmol/L; concentration range: immuno-
assay, 1.5–12.6 nmol/L; ID-LC-MS/MS, 0.6–9.8
nmol/L; Figure 3).
Discussion
We have verified the applicability of the first auto-
mated immunoassay specified for the quantification
of salivary cortisol in late-night saliva samples and
report for a preliminary reference range from a pop-
ulation of apparently healthy adults. The upper limit
of this range was 8.9 nmol/L. In a two-centre impre-
cision study including two different reagent lots, a
functional detection limit (CV-20%) of approximately
5.0 nmol/L was observed for the test. The reproduci-
bility of the assay differed considerably between the
two study laboratories (Table 2). This is despite the
fact that optimal instrument and reagent handling
procedures were performed by very experienced
technicians in each centre and no evidence of tech-
nical malfunction was noted. This observation high-
lights that salivary cortisol measurement is
technically very demanding owing to the extremely
low target concentration ranges. Commercial availa-
bility of quality control materials in this low concen-
tration range of salivary cortisol is highly desirable for
routine clinical application of salivary analysis to
detect any instrument malfunctions. Inclusion of sal-
ivary cortisol measurement in national and internatio-
nal proficiency testing schemes is also warranted.
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Figure 3 Method comparison of salivary cortisol results
obtained with the Roche Cobas Cortisol assay and an isotope
dilution liquid chromatography-tandem mass spectrometry
method.
Table 3 Overview of studies on the diagnostic performance of late-night salivary cortisol measurement in diagnosing Cush-
ing’s syndrome (CS).
Reference Study population Analytical Main results
method
(8) 39 patients with proven CS RIA Upper limit of the reference range (23:00 h) 3.6 nmol/L;
73 normal subjects (DPC) mean salivary cortisol (23:00 h): normal subjects,
1.2 nmol/L, CS patients, 24.0 nmol/L; sensitivity 92%
(9) 33 patients with CS RIA Mean: normal, 2.6 nmol/L, obese, 3.6 nmol/L, CS, 25.1
30 normal volunteers (in-house) nmol/L (23:00 h); range: subjects without CS 1.7–10.8
18 obese patients nmol/L, CS patients, 5.0–59.6 nmol/L;
obese vs. CS: sensitivity 93%, specificity 93%
(10) 122 patients with CS RIA Inpatient midnight or outpatient bedtime salivary cortisol
34 outpatients (Covance) )15.2 nmol/L identified 93% of CS patients and excluded
all subjects without CS; mean bedtime (21:00–02:00 h) sali-
vary cortisol in normal subjects 7.2 nmol/L (range 5.8–15.2)
(11) 41 patients with CS RIA ROC cutoff for midnight salivary cortisol 9.7 nmol/L;
27 healthy normal-weight (Byk-Sangtec) sensitivity 93%, specificity 93% for CS diagnosis; mean
volunteers midnight salivary cortisol in subject: normal, 5.0, obese,
199 individuals with simple obesity 5.5, PC, 6.3, and CS, 26.8 nmol/L
(12) 63 patients with CS RIA Mean midnight salivary cortisol 33.9 nmol/L in CS patients
54 subjects with simple obesity (CIS) and 2.2 nmol/L in obese controls; proposed cutoff
(mean BMI 38.3 kg/m2) 5.5 nmol/L (sensitivity 100%, specificity 96%)
(13) 150 patients with CS RIA Healthy subjects 22:00 h, salivary concentration range
100 healthy subjects (INCSTAR) -2.8–8.0 nmol/L; proposed cutoff for diagnosis of CS
4.4 nmol/L (specificity 100%, sensitivity 98%)
(14) 12 patients with CS RIA Mean night-time salivary cortisol 18.9 nmol/L in CS
20 healthy volunteers (CIS) patients, 2.1 nmol/L in healthy volunteers; proposed cutoff
16 obese patients 6.1 nmol/L (sensitivity and specificity 100%)
In a previous imprecision study of the Roche Cobas
Cortisol assay for measurement of salivary cortisol
(16), a clearly lower functional detection limit of
2.0 nmol/L was found; this discrepancy may be
explained by the lower number of analytical series
(ns10) and the probable use of a single reagent lot
in this previous investigation.
Since we observed poor agreement between sali-
vary cortisol concentrations determined with the
Cobas cortisol assay and with isotope dilution ID-LC-
MS/MS, it must be emphasised that the reference
range reported here for late-night salivary cortisol in
a population of healthy volunteers is assay-specific.
Poor agreement between immunoassay results and
ID-LC-MS/MS has been described previously (17),
with substantially higher concentrations found by a
radioimmunoassay. These observations probably
result from immunoassay cross-reactivities with
endogenous steroids such as 6b-hydroxycortisol and
21-deoxycortisol (16), but in particular with conjugat-
ed derivatives of cortisol. Different degrees of such
analytical non-specificity – besides differences in the
study populations – may explain the wide range of
diagnostic cutoff values reported in previous investi-
gations of salivary cortisol concentrations (3.6–15.2
nmol/L; Table 3). The mean late-night salivary cortisol
concentration of 5.0 nmol/L found in our study in a
healthy reference population, however, is in rather
close agreement with the value of 3.6 nmol/L reported
for the same cortisol assay in a previous study (16).
Since the matrix-independent ID-LC-MS/MS tech-
nology has the potential to harmonise salivary corti-
sol measurements in routine patient care, application
of this technique to salivary cortisol measurement
should be considered for the future, although the
analysis is clearly far more demanding compared to
immunometric cortisol quantification. Nevertheless,
as summarised in Table 3, a number of studies on the
diagnostic performance of late-night salivary cortisol
measurements for diagnosing Cushing’s syndrome
by commercially available immunoassays have dem-
onstrated a useful contribution of these methods.
False-negative results, however, must be expected;
these may in particular be due to cases of Cushing’s
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syndrome with inconsistent hormone secretion (18).
Consequently, repeated sampling should be consid-
ered to increase diagnostic sensitivity (7). Falsely high
salivary cortisol concentrations can result from sam-
pling – which is normally unsupervised – earlier than
the specified late-night hour.
In the present investigation including apparently
healthy subjects, the performance of the Roche Cobas
Cortisol assay for diagnosing Cushing’s disease has
not been investigated. However, the reference range
established in the present study may serve as a pre-
liminary cutoff in the diagnostic work-up of suspected
Cushing’s syndrome using the Roche cortisol assay.
Definite cutoff concentrations for this assay should be
assessed in future studies. During the study period,
one case of histologically proven Cushing’s disease
was observed in centre 1; the late-night salivary cor-
tisol was 11.6 nmol/L in this case, and was thus only
slightly above the upper limit of the reference range
identified in our investigation.
Salivary cortisol concentrations reflect unbound
plasma cortisol concentrations and are therefore gen-
erally believed to be unaffected by variations in cor-
ticosteroid-binding globulin (CBG) concentrations
(19). Indeed, we did not find statistically significant
differences in late-night salivary cortisol concentra-
tions for women taking hormonal contraceptive drugs
compared to individuals not taking these drugs; wom-
en taking hormonal contraceptive drugs typically
have high CBG concentrations (20). Furthermore, we
did not observe a correlation between body mass
index and late-night salivary cortisol. Besides the fact
that salivary cortisol measurement seems to be large-
ly unaffected by the important inter-individual varia-
tion of CBG, the non-invasive manner of sampling by
the patient at home in a non-stressful surrounding
argues in favour of this diagnostic approach. Ship-
ment of samples to an outpatient clinic within 24 h
after sampling seems acceptable, since good stability
of cortisol in saliva has been reported (21).
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